Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin vs Aspirin + Fondaparinux in NSTEMI
NCT06710184Phase 4Recruiting
- Sponsor
- Aarhus University
- Start
- May 2025
- Primary completion
- Jan 2029
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fondaparinux in non-ST segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by Aarhus University. Primary endpoint: Composite endpoint of mortality, new myocardial infarction, and clinical deterioration resulting in acute CAG at 30 days. Started May 2025; status: recruiting.
02
Drugs
fondaparinux
03
Conditions
non-ST segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on NCT06710184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710184.